June 11th 2025, 4:30pm
By Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
June 11th 2025, 3:00pm
By Spencer Feldman
FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.
June 11th 2025, 1:00pm
By Michelle Kirschner
Patients can prepare for self-advocacy by bringing personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner.
June 10th 2025, 9:00pm
By Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
June 10th 2025, 8:00pm
By Dr. Sara M. Tolaney
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
June 10th 2025, 7:00pm
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.
June 10th 2025, 5:00pm
By Brenda Denzler
I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.
June 10th 2025, 4:00pm
By Kristie L. Kahl
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.
June 10th 2025, 3:18pm
The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer.
June 10th 2025, 1:00pm
By Aaron Gerds, MD, MS
The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.
June 9th 2025, 9:00pm
By Mary Sansone
Five years after my transplant for leukemia, I’m learning to focus on gratitude despite daily struggles, remembering that being alive is the greatest gift.
June 9th 2025, 8:00pm
Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.
June 9th 2025, 7:00pm
Natalie Schnaitmann discusses the importance of self-advocacy and access to second opinions when symptoms are dismissed among young women with cancer.
June 9th 2025, 5:00pm
By Martha Carlson
When it comes to living with cancer, your nurses make a difference.
June 9th 2025, 4:01pm
By Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
Treating EHE: What Are Your Options?
FDA Approves Application for ABT-301 in Metastatic Colorectal Cancer
Why Art Was Good Medicine for Me After a Breast Cancer Diagnosis
Revolutionizing CAR T-Cell Therapy to Improve Patient Access